Library · Metabolic & weight · Treatment of NASH and metabolic liver diseases
Efinopegdutide (HM15211 / MK-6024)
HM15211, MK-6024, LAPS-Exendin-4 analog
Dual GLP-1/glucagon receptor agonist (HM15211/MK-6024) from Hanmi, licensed to Merck, under investigation for MASH and non-alcoholic fatty liver disease, with FDA Fast Track status for NASH.
Research score 85/100. Reference only, not a dose.
- Liver Protection
- GLP-1 Agonist
- Metabolic Enhancement
- Fat Loss
- Appetite Suppression
- Gut Health
- US status
- Investigational
- Approval
- Phase 2 Clinical Trial
- Evidence
- Phase 2 trials ongoing for NASH/MASLD. Granted FDA Fast Track Designation.
- Research score
- 85 / 100
- Indication
- Investigational - NASH/NAFLD
- Origin
- South Korea
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
The published mechanism text for this entry describes a different compound, so it is left out here.
Safety file
Generally well tolerated; adverse effects are mostly gastrointestinal (nausea, vomiting), similar to other GLP-1 drugs.
- Nausea
- Vomiting
- Injection site reactions
- Decreased appetite
- Diarrhea